Debulking strategy prior to anti-BCMA/CD3 bispecific antibodies in extramedullary and/or high tumor burden RRMM: a retrospective cohort study
Sign Up to like & getrecommendations! Published in 2025 at "Blood Cancer Journal"
DOI: 10.1038/s41408-025-01365-y
Abstract: Dear Editor, Even at the era of T-cell redirecting therapies, patients with relapsed or refractory multiple myeloma (RRMM) presenting extramedullary disease (EMD) and/or high risk cytogenetic abnormalities (HRCA) constitute a particularly challenging sub-group with lower… read more here.
Keywords: prior anti; anti bcma; rrmm; bcma cd3 ... See more keywords
Abstract 3354: Preclinical evaluation of potential cytokine release syndrome and efficacy of a BCMA-CD3 bispecific antibody for the treatment of multiple myeloma in humanized mice
Sign Up to like & getrecommendations! Published in 2020 at "Immunology"
DOI: 10.1158/1538-7445.am2020-3354
Abstract: Bispecific antibodies (BsAbs) are now emerging as the next promising class of immunotherapies. BsAbs can bind simultaneously two different antigens or epitopes, which leads to a wide range of applications including redirecting T cells or… read more here.
Keywords: cytokine release; treatment; bcma cd3;
Sipavibart (AZD-3152), a COVID-19 Pre-Exposure Prophylaxis in Myeloma Treated with BCMA/CD3 Bispecific Antibodies
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-208428
Abstract: Background. Bispecific antibodies BCMA/CD3 (BsAbs) increase the risk of developing infections related to the T-cell redirecting function in Multiple Myeloma (MM). Indeed, severe COVID-19 infections were observed despite repeated COVID-19 vaccine doses. COVID-19 targeting monoclonal… read more here.
Keywords: cd3 bsabs; covid; bcma cd3; treated bcma ... See more keywords
Bispecific BCMA-CD3 Antibodies Block Multiple Myeloma Tumor Growth
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14102518
Abstract: Simple Summary Multiple myeloma accounts for approximately 10% of hematological cancers in the United States. It is a malignancy of plasma cells which accumulate in the bone marrow and produce a monoclonal protein. Novel treatments… read more here.
Keywords: cd3 antibodies; multiple myeloma; myeloma; bcma cd3 ... See more keywords